JurisdictionsTopicsUpdatesWorkflowsCompareChat with ExpertMarketplacePricing
🇬🇧🏛️

Regulatory Hierarchy

UK regulatory structure from MHRA to dispensing pharmacy

Regulatory Structure Verified 2026-04-20

Workflow steps

  1. Home Office — DLCU — Controlled drugs licensing
    Drugs Licensing and Compliance Unit. Issues all controlled drug import/export licenses, manufacturer and distributor licenses for Schedule 2 substances including cannabis.
    • Per-shipment import/export licenses
    • Standing CD licenses for manufacturers and distributors
    • Enforcement of Misuse of Drugs Act 1971
  2. MHRA — Medicines regulation
    Medicines and Healthcare products Regulatory Agency. Regulates GMP, GDP, clinical trials, and marketing authorizations. Issues WDA(H) wholesale dealer authorizations.
    • GMP inspections of UK manufacturers
    • WDA(H) for wholesale distribution
    • Marketing Authorization (MA) or Specials license
  3. NHS England / NICE — Commissioning & HTA
    NHS England commissions CBMP prescribing. NICE provides health technology assessment guidance. Funding decisions affect patient access significantly.
    • NICE guidance affects NHS funding decisions
    • Individual Funding Request (IFR) pathway for unlicensed
    • NHS England Specialised Commissioning for complex cases
  4. NHS Scotland / SMC — Scottish Medicines Consortium
    Devolved medicines commissioning for Scotland. SMC assesses medicines independently of NICE. Scotland has its own prescribing pathway for CBMPs.
    • SMC assessment independent of NICE
    • Scottish formulary decisions may differ from England
  5. NHS Wales / AWMSG — All Wales Medicines Strategy Group
    AWMSG provides independent guidance for Wales. Welsh prescribing decisions may differ from England and Scotland.
    • AWMSG assessment for NHS Wales funding
    • Separate formulary from England
  6. HSCNI — Northern Ireland
    Health and Social Care Northern Ireland. Post-Brexit, NI has unique status — may follow EU or UK rules depending on product type. Ongoing regulatory divergence.
    • NI Protocol creates dual regulatory exposure
    • Some EU rules may apply to NI-specific supply chains
  7. Licensed Pharmacies / Specials — Dispensing
    Pharmacies dispense against specialist prescriptions. Unlicensed imports may be dispensed as 'specials' under MHRA exemption. Licensed CBMPs dispensed normally.
    • Specialist Register prescriber required
    • Schedule 2 CD register at pharmacy
    • Named patient import via specials route if no MA
  8. Patients — End recipients
    Receive CBMPs via specialist prescription. Private prescribing is more common than NHS — NHS funding remains very restricted in practice despite legal access since 2018.
Import AuthorizationGMP Pathway